PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations

Learn how experts incorporate the newest evidence from ASCO 2021 on PARP inhibitor&ndash based combinations into optimal management of prostate cancer with an on-demand webcast from a live webinar plus an expert commentary podcast and downloadable slidesets with ExpressPoints slides.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.